Akesobio (康方生物) IPO Trading: Action Post Near Zero Allocation
Akesobio, a China-based biotech company, raised USD 314 million at HKD 16.18 per share. The deal has attracted strong demands from both retail...
592 Views
Akesobio IPO: Valuation Insights
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
583 Views
Akesobio (康方生物) IPO: Expect near Zero Allocation
Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...
763 Views
Akesobio IPO Initiation: The Tough Get Going
Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...
589 Views
Akesobio (康方生物) Pre-IPO: Clinical Trial Updates from PHIP
Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...
643 Views